Related Experiment Videos
Intravenous thrombolysis for acute ischemic stroke.
1University of Cincinnati Medical Center, Greater Cincinnati & Northern Kentucky Stroke Team, the Neuroscience Institute, Dept of Radiology, the University Hospital, , Cincinnati, Ohio 45267-0762, USA. tomsicta@healthall.com
Journal of Vascular and Interventional Radiology : JVIR
|April 27, 2004
Summary
Recombinant tissue-type plasminogen activator (rtPA) is an approved treatment for acute ischemic stroke within 3 hours. Emerging evidence suggests later administration and alternative methods may also be effective for stroke patients.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Acute ischemic stroke requires timely treatment.
- Intravenous recombinant tissue-type plasminogen activator (rtPA, alteplase) is the sole FDA-approved medication for acute ischemic stroke.
- Treatment is typically recommended within 3 hours of symptom onset.
Purpose of the Study:
- To provide a comprehensive review of knowledge and insights.
- To examine thrombolytic treatment strategies in stroke patients.
- To explore the efficacy of rtPA beyond the standard 3-hour window.
Main Methods:
- Literature review of existing studies.
- Analysis of data from clinical trials and observational studies.
- Synthesis of evidence on thrombolytic therapy in stroke.
Main Results:
- Intravenous rtPA is effective within the 3-hour window.
- Evidence supports the efficacy of rtPA administered later than 3 hours.
- Alternative administration methods are also being investigated for effectiveness.
Conclusions:
- Thrombolytic therapy, particularly rtPA, plays a crucial role in managing acute ischemic stroke.
- The therapeutic window for rtPA may be extended.
- Further research into varied administration methods is warranted to optimize stroke treatment.